Alberto Grua Head of Grunenthal Europe and Australia

MILAN, Sept. 22 /CNW/ - After having handled the worldwide launch of tapentadol, the innovative drug for the severe acute pain, Alberto Grua has been appointed Grunenthal Europe and Australia Executive Vice President. Beyond the responsibility of the Grunenthal subsidiaries Grunin both continents, Grua will be also a member of the Group Operating Committee of Grunenthal Corporation.

(Photo: http://www.newscom.com/cgi-bin/prnh/20100922/409552)

Previously, Grua was Responsible for marketing and sales at BayerHealthCare, and then Managing Director of the Italian subsidiary of Grunenthal.

Grua has a business background and graduated in Business Administration at Bocconi University of Milan. Grunenthal, a multinational company with head office in Aachen, Germany, is leader in pain therapy with drugs of great success. Tapentadol - discovered by Grunenthal and codeveloped with Johnson & Johnson Pharmaceutical Research & Development, L.L.C, - has been already launched in U.S., while in Europe it is ongoing marketing.

Photo:
http://www.newscom.com/cgi-bin/prnh/20100922/409552

For further information:

Maria D'Acquino, [phone]